


PRE-EXPOSURE PROPHYLAXIS (PrEP)

HIV prevention among gay men, other men who have sex with men and trans-women in the UK

Data published from the PROUD study shows that the anti-retroviral drug Truvada (containing emtricitabine and tenofovir disoproxil fumarate), used as PrEP reduces the risk of acquiring HIV



1 in 17 MSM
aged 15 - 59
in the UK living
with HIV

2800 MSM in UK newly infected
with HIV in 2013

Protection
offered against
HIV by PrEP

86%

No significant difference
in STIs among MSM on PrEP
and those not

The PROUD study recruited 545 HIV negative gay men, other MSM and trans-women at 13 sexual health clinics in England between November 2012 and April 2014 (www.proud.mrc.ac.uk/). Volunteers were randomised to receive PrEP either immediately or after 12 months of follow-up. By October 2014, there had been a total of 22 HIV infections, 3 in the group randomised to PrEP and 19 in the group randomised to wait for a year. This equates to 1.3 infections per 100 people followed up for a year in the group given PrEP, and 8.9 infections per 100 people followed up for a year in the group who did not receive PrEP.

For the UK HIV situation see 'HIV in the United Kingdom: 2014 Report' available at:
www.gov.uk/government/uploads/system/uploads/attachment_data/file/401662/2014_PHE_HIV_annual_report_draft_Final_07-01-2015.pdf